Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
William Bara-JimenezThomas N Chase

Abstract

Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease.

References

Aug 1, 1984·Neurology·C G GoetzH L Klawans
Apr 11, 1997·European Journal of Pharmacology·M E ReithN H Chen
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·M JaberM G Caron
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·R A Hauser, T A Zesiewicz
Sep 17, 2002·European Journal of Pharmacology·Matthew J HansardPeter Jenner
Aug 13, 2003·Neurology·W Bara-JimenezT N Chase

❮ Previous
Next ❯

Citations

Feb 6, 2008·Journal of Neural Transmission·G LinazasoroJ A Ruiz Ortega
Oct 24, 2006·Nature Clinical Practice. Neurology·Carlo ColosimoAlfredo Berardelli
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
Nov 19, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Lieuwe AppelBengt Långström
Dec 13, 2006·Expert Opinion on Investigational Drugs·Roberto ScatenaBruno Giardina
May 11, 2005·Expert Opinion on Investigational Drugs·Spiros Konitsiotis
Mar 27, 2015·Parkinson's Disease·Philippe HuotJonathan M Brotchie
May 18, 2016·The Journal of Pharmacology and Experimental Therapeutics·Philippe HuotJonathan M Brotchie
Jul 9, 2016·Progress in Neurobiology·Philippe De DeurwaerdèreMark J Millan
Nov 1, 2009·Expert Review of Clinical Pharmacology·Livia Dézsi, László Vécsei
Aug 13, 2014·Therapeutic Advances in Drug Safety·Bernard Man Yung CheungNithushi Rajitha Samaranayake
Jun 8, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·William Bara-JimenezThomas N Chase
Dec 7, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserVictor L Konyago
Apr 14, 2011·British Journal of Pharmacology·Susan Duty, Peter Jenner
Feb 28, 2007·British Journal of Clinical Pharmacology·Thorsten LehrCharlotte Kloft
Sep 7, 2005·CNS Drugs·Stacy S Wu, Steven J Frucht
Aug 4, 2006·The Journal of Pharmacology and Experimental Therapeutics·Bertha K MadrasAlan J Fischman
Apr 10, 2017·Journal of Neural Transmission·Marc Morissette, Thérèse Di Paolo
Aug 29, 2021·Pharmaceuticals·E Maruthi Prasad, Shih-Ya Hung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.